Zelapar
Generic name: selegiline hydrochloride
Treatment for: Parkinson's Disease
Valeant Pharmaceuticals Receives Approvable Letter from FDA Regarding Zelapar
COSTA MESA, Calif., October 4, 2005 - Valeant Pharmaceuticals International (NYSE:VRX) today announced that the company received an approvable letter from the U.S. Food and Drug Administration (FDA) for Zelapar (selegiline hydrochloride). The approvable letter requests additional clarification on specific issues previously addressed by Valeant. Valeant plans to meet with the FDA, promptly as they have requested, to discuss and resolve these matters.
Source: Valeant Pharmaceuticals
Click here for more information on Zelapar
Posted: October 2005
Related articles
- Zelapar Valeant Pharmaceuticals International - Treatment for Parkinson’s Disease - June 14, 2006
- Valeant Pharmaceuticals Submits Complete Response to FDA Approvable Letter for Zelapar - January 5, 2005
Zelapar (selegiline hydrochloride) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
